Big Pharma are making all efforts to preoccupy orphan drugs
By | translator Choi HeeYoung
22.07.18 06:00:32
가나다라
0
KIMCo Published 'Global Rare Disease Market Research Report
In the U.S. and Europe, they dominate the global market with strong incentives such as tax incentives and priority screening
Korea is relatively behind in development and the usage environment such as benefit policy is insufficient
New drugs are emerging one after another for rare diseases such as multiple Castleman's disease, beta thalassemia, Fabri's disease, and spinal muscular dystrophy, which were not well known and had no medicine. Global pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Roche are leading new drugs for rare diseases. It was suggested that Korea should also provide institutional support and active development in the rare disease market dominated by global companies.
◆ Global company focused on rare drugs. 26% of total sales in 2026
According to the "Global Rare Disease Market Research Report" published by KIMCo, the global orphan drugs market is expected to grow by 12% a
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)